NYSE:ANRO Alto Neuroscience (ANRO) Stock Price, News & Analysis $18.92 +0.21 (+1.13%) Closing price 06/3/2026 03:58 PM EasternExtended Trading$19.69 +0.77 (+4.05%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Alto Neuroscience Stock (NYSE:ANRO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Alto Neuroscience alerts:Sign Up Key Stats Today's Range$18.39▼$19.4350-Day Range$18.76▼$27.6652-Week Range$2.15▼$28.44Volume471,541 shsAverage Volume316,562 shsMarket Capitalization$663.97 millionP/E RatioN/ADividend YieldN/APrice Target$35.25Consensus RatingModerate Buy Company Overview Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression. Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies. By partnering with biopharmaceutical companies and academic institutions, the company seeks to de-risk clinical trials, reduce time to market and enhance go-to-market strategies for novel psychiatric medications. Ongoing collaborations focus on validating biomarkers and expanding the platform’s utility across multiple neuropsychiatric indications. Formed in the late 2010s and headquartered in New York, Alto Neuroscience has assembled a leadership team with deep expertise in neuroscience, drug development and data analytics. Under the direction of co-founder and Chief Executive Officer Marshall Brennan, the company has initiated multiple clinical programs in the United States and Europe. Alto continues to expand its global footprint through strategic partnerships and joint research agreements. As a publicly traded company on the New York Stock Exchange, Alto Neuroscience is positioned at the intersection of digital health and psychiatry. Its mission is to transform the standard of care for neuropsychiatric patients by delivering predictive tools that enable more personalized, effective treatments.AI Generated. May Contain Errors. Read More Alto Neuroscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreANRO MarketRank™: Alto Neuroscience scored higher than 40% of companies evaluated by MarketBeat, and ranked 698th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAlto Neuroscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAlto Neuroscience has a consensus price target of $35.25, representing about 86.3% upside from its current price of $18.92.Amount of Analyst CoverageAlto Neuroscience has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Alto Neuroscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Alto Neuroscience are expected to decrease in the coming year, from ($3.01) to ($3.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alto Neuroscience is -7.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alto Neuroscience is -7.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlto Neuroscience has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alto Neuroscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.18% of the float of Alto Neuroscience has been sold short.Short Interest Ratio / Days to CoverAlto Neuroscience has a short interest ratio ("days to cover") of 4.69.Change versus previous monthShort interest in Alto Neuroscience has recently increased by 1.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlto Neuroscience does not currently pay a dividend.Dividend GrowthAlto Neuroscience does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.61 News SentimentAlto Neuroscience has a news sentiment score of -0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Alto Neuroscience this week, compared to 8 articles on an average week.Search Interest6 people have searched for ANRO on MarketBeat in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Alto Neuroscience insiders have not sold or bought any company stock.Percentage Held by Insiders11.25% of the stock of Alto Neuroscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAlto Neuroscience has minimal institutional ownership at this time.Read more about Alto Neuroscience's insider trading history. Receive ANRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alto Neuroscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANRO Stock News HeadlinesAlto Neuroscience Appoints Andrew Miller to BoardMay 28, 2026 | tipranks.comAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of DirectorsMay 28, 2026 | businesswire.comA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following suit ahead of what could be a massive market shift. But they're not buying bullion or coins. They're loading up on a niche asset with far more upside potential - and the details are available right now.June 4 at 1:00 AM | Traders Agency (Ad)Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research AwardMay 15, 2026 | businesswire.comAlto Neuroscience Shareholders Shape Governance and Equity PlansMay 13, 2026 | tipranks.comAlto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 13, 2026 | businesswire.comAlto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual MeetingMay 4, 2026 | businesswire.comAlto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant DepressionApril 21, 2026 | businesswire.comSee More Headlines ANRO Stock Analysis - Frequently Asked Questions How have ANRO shares performed this year? Alto Neuroscience's stock was trading at $17.82 at the start of the year. Since then, ANRO shares have increased by 6.2% and is now trading at $18.9220. How were Alto Neuroscience's earnings last quarter? Alto Neuroscience, Inc. (NYSE:ANRO) released its earnings results on Wednesday, May, 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.24. When did Alto Neuroscience IPO? Alto Neuroscience (ANRO) raised $121 million in an initial public offering (IPO) on Friday, February 2nd 2024. The company issued 8,040,000 shares at a price of $14.00-$16.00 per share. Who are Alto Neuroscience's major shareholders? Top institutional investors of Alto Neuroscience include Commodore Capital LP (7.76%), Perceptive Advisors LLC (5.73%), Spruce Street Capital LP (4.15%) and Affinity Asset Advisors LLC (1.56%). Insiders that own company stock include Wave Global Lp Alpha, Adam Savitz and Nicholas Conrad Smith. View institutional ownership trends. How do I buy shares of Alto Neuroscience? Shares of ANRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Alto Neuroscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alto Neuroscience investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/13/2026Today6/03/2026Jefferies Global Healthcare Conference 20266/03/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ANRO's financial health is in the Green zone, according to TradeSmith. ANRO has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:ANRO Previous SymbolNYSE:ANRO CIK1999480 Webwww.altoneuroscience.com Phone(650) 200-0412FaxN/AEmployeesN/AYear Founded2019Price Target and Rating Average Price Target for Alto Neuroscience$35.25 High Price Target$50.00 Low Price Target$24.00 Potential Upside/Downside+86.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.22% Return on Assets-38.81% Debt Debt-to-Equity Ratio0.07 Current Ratio20.52 Quick Ratio20.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.87 per share Price / Book3.89Miscellaneous Outstanding Shares35,090,000Free Float31,146,000Market Cap$663.97 million OptionableN/A Beta1.22 Social Links 5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NYSE:ANRO) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
